Effectiveness and safety of the tetravalent TAK-003 dengue vaccine: a systematic review
- 1 July 2024
- journal article
- review article
- Vol. 84 (4) , 689-707
Abstract
In Argentina, the dengue virus has experienced an increase in recent years. This study aims to conduct a systematic review to assess the effectiveness and safety of the tetravalent dengue vaccine TAK-003 in this context. A systematic review of randomized controlled clinical trials comparing the effectiveness and safety of the vaccine with a placebo in the general population was conducted. The search was carried out on Epistemonikos, and two investigators independently evaluated the studies. Bias risk was assessed using Cochrane's Rob 2 tool. A meta-analysis of the results was performed, and the certainty of evidence was evaluated using the GRADE methodology. We concluded, with high certainty of evidence, that the tetravalent dengue vaccine reduces severe infections (RR 0.17, 95% CI 0.12 to 0.24) and infections by the den gue virus (RR 0.40, 95% CI 0.36 to 0.45) in a population aged <= 17 years. The vaccine may not increase the risk of serious adverse events, although it is important to note the low certainty of evidence (RR 1.04, 95% CI: 0.69-1.55). The use of the tetravalent dengue vaccine decreases the risk of severe and non-severe dengue infections in this population. However, there is low certainty of evidence regarding the vaccine's safety. The decision to vaccinate should consider the magnitude of benefits relative to the risk of infection.Keywords
This publication has 20 references indexed in Scilit:
- Consistency of immunogenicity in three consecutive lots of a tetravalent dengue vaccine candidate (TAK-003): A randomized placebo-controlled trial in US adultsVaccine, 2023
- Evaluating medical tests: introducing the Cochrane Handbook for Systematic Reviews of Diagnostic Test AccuracyCochrane Database of Systematic Reviews, 2023
- GRADE guidance 36: updates to GRADE's approach to addressing inconsistencyJournal of Clinical Epidemiology, 2023
- GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratingsJournal of Clinical Epidemiology, 2021
- Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trialThe Lancet, 2020
- Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2–17 years: a randomised, placebo-controlled, phase 2 trialThe Lancet, 2020
- Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and AdolescentsNew England Journal of Medicine, 2019
- GRADE guidelines: 13. Preparing Summary of Findings tables and evidence profiles—continuous outcomesJournal of Clinical Epidemiology, 2013
- GRADE guidelines: 12. Preparing Summary of Findings tables—binary outcomesJournal of Clinical Epidemiology, 2013
- GRADE guidelines 6. Rating the quality of evidence—imprecisionJournal of Clinical Epidemiology, 2011